ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BDRX Biodexa Pharmaceuticals PLC

1.22
0.4952 (68.32%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 70,822,736
Bid Price 1.21
Ask Price 1.23
News (1)
Company Name Stock Ticker Symbol Market Type
Biodexa Pharmaceuticals PLC BDRX NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.4952 68.32% 1.22 19:59:59
Open Price Low Price High Price Close Price Prev Close
1.66 1.14 1.74 1.30 0.7248
Trades Volume VWAP Dollar Volume Avg Volume
279,930 70,822,736  1.28  90,887,192 -
Last Trade Time Type Quantity Stock Price Currency
19:59:45 50  1.22 USD

Biodexa Pharmaceuticals PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 0.00 - 699k -7.66M - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Biodexa Pharmaceuticals

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BDRX Message Board. Create One! See More Posts on BDRX Message Board See More Message Board Posts

BDRX Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Biodexa Pharmaceuticals PLC is a United Kingdom-based drug delivery technology company. The Company is focused on improving the bio-delivery and bio-distribution of medicines. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. Biodexa Pharmaceuticals Q-Sphera technology focuses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. It has a pipeline of approximately eight earlier stage programs, MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma), MTX110 (Glioblastoma), MTX114 (Psoriasis), MTD211 (Schizophrenia, MDD) and others.

Your Recent History

Delayed Upgrade Clock